Terry Vik, M.D.

Terry Vik, M.D.

Professor of Pediatrics
Director, Childhood Cancer Survivor Program
Director, Fellowship Program in Pediatric Hematology-Oncology
Director, Clinical Pediatric Hematology-Oncology at Riley Hospital 

Phone: 317-944-8784
Email: tvik@iu.edu
705 Riley Hospital Drive, ROC 4340
Indianapolis, IN 46202



Pediatric Hematology Oncology

Areas of Interest

Global Health: Childhood Cancer Treatment Program in Kenya, Translational Research: Fostering new project development through the CTSI, Cancer Survivorship: Facilitating research with childhood cancer survivors.


I have been a faculty member of Indiana University School of Medicine and Riley Hospital for Children for over 20 years. When I am not working on various projects that are job-related, I enjoy soccer, outdoor activities with family and our dogs, or travel.


1980 BA Johns Hopkins University
1983 MD Johns Hopkins University
1986 Pediatrics UCLA Center for Health Sciences
1989 Hematology-Oncology Dana-Farber Cancer Institute, The Children’s Hospital, Boston

Honors & Awards

  • 1979 Dr. Harold Lamport Biomedical Research Prize
  • 1980 Henry Strong Denison Scholarship for Medical Research
  • 1989 NIH Physician Scientist Award
  • 2005-2014 Castle and Connelly, America’s Best Doctors for Cancer


Riley Outpatient Center
705 Riley Hospital Drive
Indianapolis, IN 46202
317-944-2143 phone
317-944-3107 fax

Research & Grants

My recent research involves improving the diagnosis and treatment of children with cancer in low-income countries. We have projects to treat children with cancer and to improve the diagnosis of leukemia through education and training of local health care workers in Kenya. We continue to seek funds to extend that work.

Locally, I am involved in the education of fellows in Pediatric Hematology-Oncology, and I work to foster their research and academic careers through their training. I am also involved in clinical drug trials of new agents for treatment of diseases in children with cancer or blood disorders.

U24 Childhood Cancer Survivor Study. NIH, Institutional Principal Investigator

UL1 Indiana Clinical and Translational Sciences Institute. NIH, Co-Investigator

Foundation Grant Childhood Leukemia in Kenya Identified Through Malaria Slide Review. Alex’s Lemonade Stand Foundation. 2012 Epidemiology Award Principal Investigator


Pradhan KR, Johnson CS, Vik TA, Sender LS, and Kreissman SG. A Novel Intensive Induction Therapy for High Risk Nwuroblastoma Utilizing Sequential Peripheral Blood Stem Cell Collection and Infusion as Hematopoertic Support. Pediatric Blood and Cancer, 46:793-802, 2006.

Vik TA. Pfluger T. Kadota R. Castel V. Tulchinsky M. Farto JC. Heiba S. Serafini A. Tumeh S. Khutoryansky N. Jacobson AF. (123)I-mIBG scintigraphy in patients with known or suspected neuroblastoma: Results from a prospective multicenter trial. Pediatric Blood & Cancer. 52(7):784-90, 2009.

Noble, SL, Sherer, E, Hannemann, RE, Ramkrishna, D, Vik, T, and Rundell, AE. Using adaptive model predictive control to customize maintenance therapy chemotherapeutic dosing for childhood acute lymphoblastic leukemia. J. Theor. Biol. 264(3):990-1002, 2010.

Spunt, SL, Grupp, SA, Vik, TA, Santana, VM, Greenblatt, DJ, Clancy, J. Berkenblit, A, Krygowski, M, Ananthakrishnan, R, Boni, JP, and Gilbertson, RJ. Phase I Study of Temsirolimus in Pediatric Patients With Recurrent/Refractory Solid Tumors. J Clin Oncol. 29(21):2933-40, 2011.

Pradhan, KR, Mund, JA Johnson, C, Vik, TA, Ingram, DA, and Case, J. Polychromatic Flow Cytometry Identifies Novel Subsets of Circulating Cells with Angiogenic Potential in Pediatric Solid Tumors. Cytometry Part B, 80B:335-338, 2011.

Creary S, Heiny M, Croop J, Fallon R, Vik T, Hulbert M, Knoderer H, Kumar M, and Sharathkumar A. Clinical course of postthrombotic syndrome in children with history of venous thromboembolism. Blood Coagulation & Fibrinolysis 23(1): 39–44, 2012

Sharathkumar, AA, Mahajerin, A, Heidt, L, Doerfer, K, Heiny, M, Vik, T, Fallon, R, and Rademaker, A. Risk-prediction tool for identifying hospitalized children with a predisposition for development of venous thromboembolism: Peds-Clot clinical decision rule. J Thromb Haemost. 10: 1326-34. 2012.

Robertson KA, Nalepa G, Yang FC, Bowers DC, Ho CY, Hutchins GD, Croop JM, Vik TA, Denne SC, Parada LF, Hingtgen CM, Walsh LE, Yu M, Pradhan KR, Edwards-Brown MK, Cohen MD, Fletcher JW, Travers JB, Staser KW, Lee MW, Sherman MR, Davis CJ, Miller LC, Ingram DA, Clapp DW. Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol. 13:1218-24. 2012

Mahajerin, A., Obasaju P., Eckert G., Vik, TA., Mehta R., and Heiny M. Thrombophilia testing in children: a 7 year experience. Pediatric Blood and Cancer. 61:523-527, 2014.